Coherus Oncology (CHRS) Minority Interest (2014 - 2018)

Coherus Oncology has disclosed Minority Interest across 5 years of filings, most recently posting -$1.3 million for Q2 2018.

• Minority Interest for Q2 2018 came in at -$1.3 million, down 4.52% year-over-year; the trailing twelve-month figure through Jun 2018 was -$1.3 million (down 4.52% YoY), and the FY2017 annual result was -$1.3 million, down 9.89% from the prior year.
• Minority Interest came in at -$1.3 million for Q2 2018 at Coherus Oncology, down from -$1.3 million in the prior quarter.
• In the past five years, Minority Interest ranged from a high of -$44000.0 in Q4 2014 to a low of -$1.3 million in Q2 2018.
• The 5-year median for Minority Interest is -$1.1 million (2016), against an average of -$872250.0.
• Across the five-year window, Minority Interest tumbled 1540.91% in 2015 and decreased 4.52% in 2018, its largest moves.
• Coherus Oncology's Minority Interest stood at -$44000.0 in 2014, then plunged by 1540.91% to -$722000.0 in 2015, then tumbled by 62.47% to -$1.2 million in 2016, then fell by 9.89% to -$1.3 million in 2017, then retreated by 4.03% to -$1.3 million in 2018.
• The last three Minority Interest figures came in at -$1.3 million (Q2 2018), -$1.3 million (Q1 2018), and -$1.3 million (Q4 2017), per Business Quant data.